White paper: QuantuMDx SARS-CoV-2 RT-PCR Detection Assay – clinical performance evaluation

Title: QuantuMDx SARS-CoV-2 RT-PCR Detection Assay – design, analytical and multi-centre evaluation of clinical performance White paper overview: After completing the development of our SARS-CoV-2 RT-PCR Detection Assay, QuantuMDx undertook

Share
QuantuMDx attains CE-IVD marking for SARS-CoV-2 Test

QuantuMDx Group today announces its SARS-CoV-2 detection assay has been CE-IVD marked under the In Vitro Diagnostics Directive (98/79/EC), enabling use within the European Union. QuantuMDx has now registered the

Share
QuantuMDx launches rapid, sensitive SARS-CoV-2 test

QuantuMDx Group today announces the launch of its sensitive SARS-CoV-2 assay for laboratory use, which delivers a result in approximately 70 minutes. Working with British manufacturing partner Biofortuna Limited, QuantuMDx

Share
QuantuMDx: Leadership changes and business update

QuantuMDx today announces a business update and the appointments of Jonathan O’Halloran as Chief Executive Officer and Neil Butler as Chairman of the Board, as the company begins its transition

Share
QuantuMDx and Ontera collaborate to advance sepsis diagnosis

Improving outcomes for sepsis patients and promoting antibiotic stewardship QuantuMDx and Ontera, have announced a collaboration to create a next-generation solution for blood stream infection and drug resistance detection. The

Share
FIND collaborates with QuantuMDx and SpeeDx

Investigating feasibility of rapid, low-cost STI diagnostics development QuantuMDx and SpeeDx today announced a collaboration with the Foundation for Innovative New Diagnostics (FIND). The global non-profit organization drives development and

Share
QuantuMDx appoints Neil Butler as a Non-Executive Director

QuantuMDx has announced that Neil Butler has joined its Board as an Independent Non-Executive Director. Neil is a seasoned healthcare executive with over 20 years’ experience working in, and managing,

Share
QuantuMDx develops QC analytics system for cell & gene therapies

QuantuMDx Group Ltd has announced plans to expand the potential of its Q-POC™ technology and develop a quality control analytics system for cell and gene therapies (C&GTs), to be evaluated

Share
QuantuMDx & St George’s begin field study: cervical cancer screening test

 To coincide with Cervical Cancer Prevention Week, QuantuMDx Group has announced the start of a field study with St George’s, University of London, to evaluate its human papilloma virus (HPV)

Share
QuantuMDx and Molbio announce Memorandum of Understanding (MoU)

  QuantuMDx Group Limited and Molbio Diagnostics Private Limited have signed a memorandum of understanding (MoU) to explore opportunities for joint working in infectious disease diagnostics, with an initial focus

Share